CAR-NK cells: A promising cellular immunotherapy for cancer.

Autor:	Xie G; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Dong H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Microbiology and Immunology, Harvard Medical School, Boston, MA 02115, USA., Liang Y; Division of Hematologic Malignancies and Transplantation, Dana Farber Cancer Institute, Boston, MA 02115, USA., Ham JD; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Rizwan R; Division of Hematologic Malignancies and Transplantation, Dana Farber Cancer Institute, Boston, MA 02115, USA. Electronic address: rizwan_romee@dfci.harvard.edu., Chen J; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: jchen@mit.edu.
Jazyk:	angličtina
Zdroj:	EBioMedicine [EBioMedicine] 2020 Sep; Vol. 59, pp. 102975. Date of Electronic Publication: 2020 Aug 24.
DOI:	10.1016/j.ebiom.2020.102975
Abstrakt:	Natural Killer (NK) cells and CD8 + cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for 'off-the-shelf' manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer. Competing Interests: Declaration of Competing interest All of authors declare no competing interests. (Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu